Background pattern of a brain with neural connections

Team Ulusoy

Development and Validation of Labeled Antibodies Against Mitochondrial and Oxidative Stress-Related Targets for Parkinson’s Disease Research

2026-Present

High-affinity specific antibodies targeting key cellular pathways are an essential technical tool to understand Parkinson’s disease (PD) pathophysiology. Albeit commercial antibodies exist, their specificity and reliability have not been thoroughly optimized for PD research. Furthermore, there is a demand for labeled antibodies that help visualize and quantify PD-linked markers, accelerating disease progression research and drug development. We aim to develop a versatile, multiplex-ready toolkit of knockout-validated, quality-controlled labeled antibodies, specifically optimized for applications such as flow cytometry and cyclic immunohistochemistry, allowing researchers to interrogate these targets in a cell-type and subcellular compartment–specific manner.

Tags
AntibodiesMitochondriaOxidative stress

Contributions

Stay tuned—this is where the team’s scientific contributions will be shared.

Accolades

Check back soon to see how this team is being recognized.

In the News

DZNE Awarded around 3.5 Million US Dollars in Funding for Parkinson’s Research

DZNE Awarded around 3.5 Million US Dollars in Funding for Parkinson’s Research

06/29/2026 — DZNE is coordinating a German-US consortium to develop new molecular tools for Parkinson’s research. In this context, DZNE is receiving around 3.5 million US dollars in funding from the U.S.-based initiative Aligning Science Across Parkinson’s (ASAP), in collaboration with The Michael J. Fox Foundation for Parkinson’s Research. The consortium will join the Collaborative Research Network (CRN), an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

04/28/2026 — Today, Aligning Science Across Parkinson’s (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.